Compare Cassava Sciences Inc (FLNA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Viatris Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Viatris Inc trades at $17.18 (market cap $19.44B). The key difference: Viatris Inc is far larger — about 365.8× Cassava Sciences Inc's market cap, and Viatris Inc pays a 2.88% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | VTRS | |
|---|---|---|
Market Cap | $53.14M | $19.44B |
Sector | Health | Health |
52-Week High | $4.64 | $17.39 |
52-Week Low | $1.09 | $8.74 |
Enterprise Value | -$33.43M | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
